255 related articles for article (PubMed ID: 17968474)
1. Post-coital gross hematuria: an unusual presentation of benign prostatic hyperplasia.
Chen YH; Lin PY; Cheng YS; Lin JS; Lin YM
Asian J Androl; 2007 Nov; 9(6):856-8. PubMed ID: 17968474
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia.
Kearney MC; Bingham J; Bergland R; Meade-D'Alisera P; Puchner PJ
J Urol; 2002 Jun; 167(6):2489-91. PubMed ID: 11992064
[TBL] [Abstract][Full Text] [Related]
3. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.
Roehrborn CG; Lukkarinen O; Mark S; Siami P; Ramsdell J; Zinner N
BJU Int; 2005 Sep; 96(4):572-7. PubMed ID: 16104912
[TBL] [Abstract][Full Text] [Related]
4. Dutasteride significantly improves quality of life measures in patients with enlarged prostate.
O'Leary MP; Roehrborn CG; Black L
Prostate Cancer Prostatic Dis; 2008; 11(2):129-33. PubMed ID: 17592479
[TBL] [Abstract][Full Text] [Related]
5. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
Marberger M
Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
[TBL] [Abstract][Full Text] [Related]
6. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
7. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
8. Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Brown CT; Nuttall MC
Int J Clin Pract; 2003 Oct; 57(8):705-9. PubMed ID: 14627182
[TBL] [Abstract][Full Text] [Related]
9. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
Seftel A; Rosen R; Kuritzky L
Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
[TBL] [Abstract][Full Text] [Related]
10. [Medical therapy of benign prostatic hyperplasia].
Altarac S
Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940
[TBL] [Abstract][Full Text] [Related]
11. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
12. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
Ravish IR; Nerli RB; Amarkhed SS
Arch Androl; 2007; 53(1):17-20. PubMed ID: 17364459
[TBL] [Abstract][Full Text] [Related]
13. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
14. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report.
Puchner PJ; Miller MI
J Urol; 1995 Nov; 154(5):1779-82. PubMed ID: 7563345
[TBL] [Abstract][Full Text] [Related]
15. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
[TBL] [Abstract][Full Text] [Related]
16. [Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?].
Grigor'ev ME; Konorev VA
Urologiia; 2007; (6):90, 92-5. PubMed ID: 18652016
[No Abstract] [Full Text] [Related]
17. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride.
Foley SJ; Soloman LZ; Wedderburn AW; Kashif KM; Summerton D; Basketter V; Holmes SA
J Urol; 2000 Feb; 163(2):496-8. PubMed ID: 10647664
[TBL] [Abstract][Full Text] [Related]
18. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of finasteride in the treatment of hematuria associated with benign prostatic hypertrophy].
Palou Redorta J; Gausa Gascon L; Salvador Bayarre J; Millán Rodríguez F; Segarra Tomás J; Villavicencio Mavrich H
Arch Esp Urol; 2002 Oct; 55(8):895-9. PubMed ID: 12455279
[TBL] [Abstract][Full Text] [Related]
20. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia.
Memis A; Ozden C; Ozdal OL; Guzel O; Han O; Seckin S
Urol Int; 2008; 80(2):177-80. PubMed ID: 18362489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
